2Baharlou R, Ahmadi Vasmehjani A, Dehghani A, et al. Re- duced interleukin-17 and transforming growth factor Beta levels in peripheral blood as indicators for following the course of bladder cancer [J]. Immune Netw, 2014, 14 (3) : 156-163.
3James AC,Holt SK,Wright JL,et al. Burden and timing of venothrombolic events in patients younger than 65 years undergoing radical cystectomy for?bladder cancer [J]. Urol Oncol, 2014,32(6) : 815-819.
4Hu M, Jacobs BL, Montgomery JS, et al. Sharpening the focus on causes and timing of readmission after radical cys- tectomy for bladder cancer [J]. Cancer, 2014,120(9) : 1409- 1416.
5Benner C, Greenberg M, Shepard N, et al. The natural his- tory of symptoms and distress in patients and families fol- lowing cystectomy for treatment of muscle invasive blad- der cancer [J]. J Urol,2014,191(4) :937-942.
6Waller J,Pattison N. Men's experiences of regaining uri- nary continence following robotic-assisted laparoscopic prostatectomy (RALP) for localised prostate cancer: a qualitative phenomenological study [J]. J Clin Nurs,2013, 22(3-4) : 368-378.
7Fitch MI, Miller D, Sharir S, et al. Radical cystectomy for? bladder cancer: a qualitative study of patient experiences and implications for practice [J]. Can Oncol Nurs J,2010, 20(4) : 177-187.
8Antoniewicz AA, Alivizatos G, Zapala L, et al. Green- Light laser in the treatment of lower urinary tract symp- toms due to benign prostatic enlargement [J]. Expert Rev Med Devices, 2011,8(2) : 139-147.
9Hsu T, Black PC, Chi KN, et al. Treatment of muscle-in- vasive bladder cancer in Canada: a survey of genitouri- nary medical oncologists and urologists [J]. Can Urol As- soc J,2014,8(9-10) :309-316.
10Stanescu F, Geavlete B, Georgescu D, et al. NBI-plasma vaporization hybrid approach in bladder cancer endo- scopic management [J]. J Med Life,2014,7(2) :155-159.
